Eta-1 (Osteopontin): An Early Component of Type-1 (Cell-Mediated) Immunity

Samy Ashkar(Boston Children's Hospital), Georg F. Weber(Dana-Farber Cancer Institute), Vassiliki Panoutsakopoulou(Harvard University), Marie Sanchirico(Harvard University), Marianne Jansson(Harvard University), Samer Zawaideh(Boston Children's Hospital), Susan R. Rittling(Rutgers, The State University of New Jersey), David T. Denhardt(Rutgers, The State University of New Jersey), Melvin J. Glimcher(Boston Children's Hospital), Harvey Cantor(Harvard University)
Science
February 4, 2000
Cited by 1,127

Abstract

Cell-mediated (type-1) immunity is necessary for immune protection against most intracellular pathogens and, when excessive, can mediate organ-specific autoimmune destruction. Mice deficient in Eta-1 (also called osteopontin) gene expression have severely impaired type-1 immunity to viral infection [herpes simplex virus-type 1 (KOS strain)] and bacterial infection (Listeria monocytogenes) and do not develop sarcoid-type granulomas. Interleukin-12 (IL-12) and interferon-gamma production is diminished, and IL-10 production is increased. A phosphorylation-dependent interaction between the amino-terminal portion of Eta-1 and its integrin receptor stimulated IL-12 expression, whereas a phosphorylation-independent interaction with CD44 inhibited IL-10 expression. These findings identify Eta-1 as a key cytokine that sets the stage for efficient type-1 immune responses through differential regulation of macrophage IL-12 and IL-10 cytokine expression.


Related Papers

No related papers found

Powered by citation graph analysis